Jacquelyn Cobb is an associate editor and reporter with The Cancer Letter. She joined the publication in 2022.
Before joining The Cancer Letter, Jacquelyn worked at Dana-Farber Cancer Institute as a research data specialist in translational gastrointestinal oncology. She graduated with an M.Sc. in precision medicine and biomedical technology as an Erasmus Mundus Scholar in July, 2022.
Jacquelyn graduated from Lafayette College in 2019 with a bachelor’s degree in biology and English. During college, she was editor-in-chief of the undergraduate-led research journal,The Journal of Young Investigators. After college, she received a Fulbright Fellowship and spent nine months in Kolkata, India as an English teaching assistant.
Before joining The Cancer Letter, Jacquelyn worked at Dana-Farber Cancer Institute as a research data specialist in translational gastrointestinal oncology. She graduated with an M.Sc. in precision medicine and biomedical technology as an Erasmus Mundus Scholar in July, 2022.
Jacquelyn graduated from Lafayette College in 2019 with a bachelor’s degree in biology and English. During college, she was editor-in-chief of the undergraduate-led research journal,The Journal of Young Investigators. After college, she received a Fulbright Fellowship and spent nine months in Kolkata, India as an English teaching assistant.
Latest Stories
Cancer Policy
Sen. Bill Cassidy (R-LA), a key Senate health leader, June 23 called for the meeting of the Advisory Committee on Immunization Practices to be delayed, citing concerns over the committee members’ lack of directly relevant experience and their potential bias against some vaccines.
As biomedical research at NIH faces an existential threat from the Trump administration, an entrepreneur is winning over allies for what he describes as a “simple idea” that could introduce a massive new infusion of money for innovation in medicine.
Regulatory News
In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...
Clinical
Cannabis use disorder is associated with a dramatically increased odds of death within five years of diagnosis in people with colorectal cancer, a recent observational study found.Â
Cancer Policy
NIH Director Jayanta Bhattacharya “prioritizes political momentum over human safety and faithful stewardship of public resources,” a group of Nobel laureates and over 300 NIH employees wrote in a letter.
Cancer Policy
In November 2024, Bobby Mukkamala was giving a routine talk to a group of physicians and medical students when his language suddenly became garbled. For a minute or two, he stopped making any sense.
Cancer Policy
HHS Secretary Robert Kennedy Jr. asserted that under his leadership, FDA will “end the war” against alternative medicine.
Two years ago, Dan Theodorescu made a discovery that could alter biology textbooks: The Y chromosome, widely considered to be a “functional wasteland,” has functions beyond sex determination—and in fact plays a role in cancer biology.Â
Cancer Policy
Booth 10025 became an unlikely crowd magnet at the exhibit hall at the annual meeting of the American Society of Clinical Oncology that ended earlier this week.
Cancer Policy
Nearly 11 million people will become uninsured if reconciliation bill passes as is, CBO report finds
The nonpartisan Congressional Budget Office released a report estimating the budgetary effects of President Trump’s “One Big Beautiful Bill Act,” which was passed in the House May 22.Â
Cancer Policy
Mehmet Oz, Robert F. Kennedy Jr., Marty Makary, Jayanta Bhattacharya, and Vinayak Prasad at an FDA Roundtable on Cell and Gene Therapy, June 5.Speaking at an FDA Roundtable on Cell and Gene Therapy, FDA Commissioner Marty Makary questioned the construct of “levels of evidence” as artificial and dogmatic, saying that n-of-1 “stories” can drive regulatory decisions.
Cancer Policy
FDA rolled out a generative artificial intelligence tool designed to help employees across the agency “work more efficiently.”Â
Cancer Policy
In the morning of May 28, presumably before turning off the lights and closing the office door, someone at the now defunct NCI Office of Communications and Public Liaision decided to post a farewell message to the cancer community. The message, posted on multiple social media accounts, read: We’re taking a pause here - but...
Cancer Policy
President Trump has issued an executive order, titled “Restoring Gold Standard Science,” which “ensures that agencies practice data transparency, acknowledge relevant scientific uncertainties, are transparent about the assumptions and likelihood of scenarios used, approach scientific findings objectively, and communicate scientific data accurately.”
Cancer Policy
A recent report from the Make America Healthy Again Commission cites ultraprocessed foods, electromagnetic radiation, and herbicides as possible reasons for increased cancer incidence in children.
Regulatory News
In two back-to-back, all-day meetings, the FDA Oncologic Drugs Advisory Committee considered four thorny applications that the agency appeared to have been saving up as a result of the pause in activity that followed President Trump’s return to office.
PAMN becomes CMCA—the Cancer Marketing & Communications Association—as its size and scope expand
As the leaders of the Public Affairs & Marketing Network set out to develop a strategic plan four years ago, they had to confront one surprising challenge.
Capitol Hill
In back-to-back congressional hearings earlier this week, HHS Secretary Robert F. Kennedy Jr. said that the massive staff and budget cuts over which he has presided during his nearly four months on the job as well as even bigger cuts still looming on the horizon are a part of a single plan.
Clinical
Natalie Phelps, a 43-year-old mother of two, has stage 4 colorectal cancer. She has become a central figure in the controversy over the dysfunction the Trump administration’s RIFs and budget cuts have brought to NIH.Â
Cancer Policy
On May 12, President Trump signed an executive order directing the administration to communicate most-favored-nation drug price targets to pharmaceutical manufacturers for sales in the United States.
How is the enterprise of cancer research doing after the first 100 days of the Trump administration?
Cancer Policy
Over $180 million in NCI grants have been terminated between Feb. 28 and April 8, according to a systematic review published in JAMA May 8.Â
Cancer Policy
In an interview with Science, NIH Director Jay Bhattacharya said that his time at the NIH has been a “tough period”—especially for him.Â
Cancer Policy
The American Association for Cancer Research called on Congress to stand up in unified opposition to President Trump’s FY2026 budget proposal for NIH, and to instead allocate a robust funding increase to $51.3 billion for the NIH (The Cancer Letter, May 2, 2025).
Cancer Policy
Julie Fleshman, president and CEO of the Pancreatic Cancer Action Network, sent a letter to Congress in response to the proposed NIH budget cuts.Â
Cancer Policy
Scott Gottlieb, Mark McClellan warn of the major challenges created by planned reorganization of FDA
Scott GottliebMark B. McClellanTwo former FDA commissioners—Scott Gottlieb and Mark B. McClellan—warned that the Trump administration’s proposal to restructure FDA by consolidating the different product centers that review drugs, biologics, animal health, tobacco, and medical devices into a single regulatory office would lead to major challenges.
Cancer Policy
FDA announced a meeting of the Oncologic Drugs Advisory Committee May 20 and 21. It will be the first ODAC meeting since President Trump was inaugurated.
Clinical
Three years ago, researchers from Memorial Sloan Kettering Cancer Center published stunning results: For the 5% of rectal cancer patients whose tumors are mismatch-repair deficient, neoadjuvant dostarlimab-gxly (Jemperli) has the makings of a silver bullet.
Free
When Kelly Spill was eight months pregnant, she experienced some constipation and noticed blood in her stool. Her OBGYN wasn’t worried.
White House
An updated version of President Trump’s budget request published on May 2 comes as a disappointment for those who hoped that the White House would rethink the draconian cuts contained in an earlier, confidential version of the document that ended up being leaked to the press.Â
Cancer Policy
The Association of American Cancer Institutes sent a letter to NIH Director Jay Bhattacharya expressing concern about the proposed NIH policy change that would centralize all grant reviews to the Center for Scientific Review (The Cancer Letter, March 7, 2025).Â
Cancer Policy
HHS spokesperson Andrew Nixon told NPR that HHS will reduce all contracts by 35%.Â
Cancer Policy
The National Cancer Registrars Association launched an advocacy campaign asking the public to contact their representatives and insist upon the protection of essential public health professionals and adequate funding of cancer prevention and research.
Cancer Policy
On April 21, Women’s Health Initiative investigators were informed that HHS would be terminating the WHI Regional Center contracts at the end of the current fiscal year.
Cancer Policy
The Association for Clinical Oncology has reached out to the new leaders of federal health agencies to ensure continued progress in cancer care, research, and patient access, the organization said.
Cancer Policy
The Department of Government Efficiency has started requiring HHS grantees to provide justifications in order to receive payouts for already awarded grant money.
Cancer Policy
NIH, in a recent notice, prohibits grant recipients from operating programs that promote DEI or “discriminatory equity ideology,” or engage in “discriminatory prohibited boycott.”Â
Cancer Policy
Federal judges in Maryland, New Hampshire and Washington, DC, blocked the Trump administration from following through on threats to cut off funding to universities that engage in DEI efforts.
Cancer Policy
Sethuraman Panchanathan, director of the National Science Foundation, will resign from the position 16 months before the scheduled end of his six-year term.Â
Regulatory News
As he addressed FDA employees, HHS Secretary Robert F. Kennedy Jr. described the Trump era as a “generational opportunity to make the regulatory agency live up to its foundational ideals” and emerge from the morass of what he described as the “deep state.”
Clinical
Immunotherapy has changed the course of blood cancers and melanomas, but is stubbornly ineffective for the treatment of most epithelial solid cancers—the cancers that kill about 90% of the more than 600,000 Americans who die of cancer each year.
The day before health economist Jay Bhattacharya stepped into his new role as NIH director, he sent a document to his employees outlining his top five priorities for the department, which included “reproducibility” and “transparency,” two themes he discussed at his confirmation hearings (The Cancer Letter, March 7, 2025).
Conversation with The Cancer Letter
Brian J. Druker summits Mt. Hood in 1996The last time Brian J. Druker ran a marathon, his daughter, Julia, was six months old.
In the Archives
Credit: NCI/Linda BartlettIn an oral history conducted by FDA in September 2013, Andrew C. von Eschenbach recounted his eight-month stint in a dual role as both FDA acting commissioner and NCI director.Â
Capitol Hill
The U.S. Department of Health and Human Services announced that it is making sweeping revisions by cutting personnel, centralizing functions, and consolidating divisions.Â
News Analysis
The March 15 continuing resolution has gutted the Department of Defense Congressionally Directed Medical Research Program. The program’s funding was cut by 57%, compared to Fiscal Year 2024 levels—from $1.5 billion to $650 million.Â
News Analysis
For over a month since President Trump announced his intent to impose aggressive new tariffs on America’s friends and foes alike, lobbyists for hospitals, medical societies, and makers of branded and generic drugs have been trying to convince him to rethink.
Regulatory News
Government work isn’t what it used to be.
Capitol Hill
Amid the flood zone of today’s Washington, the confirmation hearing for Jayanta (Jay) Bhattacharya’s nomination as director of NIH was remarkably calm.
Regulatory News
In a speech before a joint session of Congress, President Trump briefly addressed pediatric cancer, pointing to a 13-year old brain tumor survivor, Devarjaye “DJ” Daniel, who was watching from the gallery, making his dream come true by naming him a Secret Service agent.
Capitol Hill
The House Republicans have narrowly pushed through a FY25 budget resolution, setting off a tangle of life-and-death sequelae for access to health insurance through Medicaid and Obamacare, and through a second-order effect, biomedical research.Â
Conversation with The Cancer Letter
Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States. Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...
In the Archives
In 1984, Peter Greenwald brought a concern about food labeling to FDA. He felt that the “standards of identity”—the standards a food product must meet in order to be marketed under a certain name—went against the best available public health evidence.
White House
As NCI employees and others at HHS were receiving notices of termination, national cancer organizations called on Congress “to restore stability to NIH.”
Free
Nearly 30 years ago, while completing an assignment for his master’s degree in public health, Brian Rivers discovered he had a family history of prostate cancer.Â
White House
Earlier this week, Robert F. Kennedy Jr. was confirmed as secretary of Health and Human Services amid many resignations at federal health agencies and cancellations of NIH and NCAB meetings. All of this happened at a time when the Trump administration is reportedly preparing to fire thousands of HHS workers.
White House
The web page for the FDA Office of Minority Health and Health Equity is no more. The pages for the NCI Diversity Training and Biomedical Workforce Development Branch and Disparities Research Branch are kaput as well.
Over the last 45 years, prevention and screening interventions have made a greater contribution to averting cancer deaths than have improvements in treatment, according to a modeling study led by researchers at NCI.Â
By Yiqing Wang and Jacquelyn Cobb
Clinical
The National Comprehensive Cancer Network published its first patient resource aimed at informing people about the latest recommendations around hereditary and familial cancer risk. The document provides guidance on testing for inherited genetic mutations that can raise the risk of cancer.
The NCI Human Tumor Atlas Network (HTAN) has published a cluster of papers intended to advance the framework of spatial omics, the science of profiling morphological and molecular features of human cancers in two and three dimensions.
The NCI Board of Scientific Advisors approved four new concepts and five reissue concepts at a joint meeting of the BSA and the National Cancer Advisory Board Dec. 2-3.
NCI Director's Report
NCI is temporarily reducing its paylines as the federal government is being funded at FY2024 levels via a continuing resolution that extends until Dec. 20, delaying the budgeting process for most federal agencies in the new fiscal year.
One year after the Centers for Medicare & Medicaid Services made the decision to pay for patient navigation services, data from early adopters show that navigation services are leading to better outcomes, significant cost savings for healthcare systems, and mitigation of health inequities.
Clinical
The San Antonio Breast Cancer Symposium will focus on doing the same with less—less surgery, less radiation, while maintaining clinical outcomes. The symposium will take place Dec. 10-13 in San Antonio, TX.
Conversation with The Cancer Letter
When Judith O. Hopkins started medical school in 1974, she had to sign a contract promising to not get pregnant. This was not the most egregious form of sexism she would face in her career. Seeking a residency in emergency medicine in 1977, she was told point blank that she would not be considered. “I...
The National Academy of Medicine announced the election of 90 regular members and 10 international members during its annual meeting.Â
Clinical
In an industry that set its sights on reshaping cancer detection, GRAIL Inc. had the appearance of a pioneer.
Clinical
If clinical research were anything like fly fishing, the scientific question that EA3163 trial attempted to answer might be considered “the one that got away”.
Regulatory News
The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated as a first-line treatment for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.
Regulatory News
The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.
A law group associated with conservative causes and funded by leading conservative donors has sued NIH, HHS, and the National Library of Medicine, demanding that the institutions address PubMed’s inability to display all papers authored by researchers who have published under multiple names.
Tumors are able to form without any DNA mutations, according to a recent proof-of-principle study performed in flies. Epigenetic changes alone—even temporary alterations—induced permanent cancer cell fate.
NCI Director's Report
NCI Director Kimryn Rathmell has released her professional judgment budget proposal, requesting nearly $11.5 billion—the same amount as last year’s proposal prepared by her predecessor, Monica Bertagnolli.
Free
Elizabeth Comen originally set out to write a book about the wellness industry, but ended up writing a different book altogether.
Health Equity
VOICES of Black Women, the largest population study of Black women in the United States, will be the first of American Cancer Society’s large-scale population studies to be initiated using an AI-driven data management platform—promising to bring observational cancer research out of the age of Excel data files and email sharing.
Regulatory News
The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
Health Equity
The Centers for Medicare and Medicaid Services said it intends to start providing additional reimbursement for some high-cost drugs for people with Medicare who receive care at Indian Health Service or tribal hospitals, beginning Jan. 1, 2025.
Obituary
Edward Sondik, an electrical engineer by training, followed a career path that led him to top public health positions.He was a director of the National Center for Health Statistics at CDC, an acting director of NCI, and a deputy director of the NCI Division of Cancer Prevention and Control.
Clinical
Treatment with an indefinite course of osimertinib dramatically improves progression-free survival for patients with stage 3 non-small cell cancer, according to the results of the LAURA trial. The median PFS was 39.1 months in the osimertinib group, compared to 5.6 months with the placebo group.
By Jacquelyn Cobb and McKenzie Prillaman
Women make up more than half of the U.S. population and are well represented in medicine—but not so much in the top jobs in oncology.
Cancer center communicators—public relations, marketing, and communications experts—are indispensable players in the implementation of the National Cancer Plan, said Peter Garrett, director of NCI’s Office of Communications and Public Liaison.
Clinical
Homologous recombination deficiency tests are used routinely in the clinic to determine which patients get PARP inhibitors.
Conversation with The Cancer Letter
Homologous recombination deficiency tests are available from multiple vendors, and every day they are used to determine whether patients stand to benefit from PARP inhibitors.Â
Free
Lillian L. Siu discovered her passion while perusing employment ads in the Journal of Clinical Oncology.
Regulatory News
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.Â
Conversation with The Cancer Letter
Sylvester’s C. Ola Landgren: “I was convinced that this is really the way to go”
Clinical
An analysis by researchers from the International Agency for Research on Cancer casts doubt on validity of an endpoint used in key studies of multi-cancer detection tests.
White House
A coalition of health and physician groups earlier this week filed a lawsuit seeking to force FDA to finalize a long-delayed final rule banning menthol cigarettes.
After a year of trying to sell his mansion, former Washington Commanders owner Daniel Snyder opted to donate it to the American Cancer Society.
Regulatory News
The FDA Oncologic Drugs Advisory Committee voted overwhelmingly in favor of expanding the indications of two chimeric antigen receptor engineered T-cell therapies for multiple myeloma that showed improvement in progression-free survival, but also reported a higher number of early deaths on the experimental arm.Â
Regulatory News
The FDA Oncologic Drugs Advisory Committee voted 12:2 to recommend approval of the drug imetelstat for a myelodysplastic syndrome indication.
NCI and Cancer Research UK awarded $125 million in total funding through the Cancer Grand Challenges program, supporting research on cancer inequities, early-onset cancers, solid tumors in children, and T-cell receptors. The $125 million investment marks the Cancer Grand Challenges program’s largest funding round to date.
Health Equity
A study of over 100,000 United States veterans has found that housing for veterans with lung and colorectal cancer was associated with a survival benefit.Â
More than a decade ago, Glenn Begley and Lee Ellis published a paper with astounding findings: of 53 “landmark” studies, only six, or 11%, were reproducible, even with the same reagents and the same protocols—and even, sometimes, in the same laboratory—as the original study.
Seventeen scientists have received NCI’s 2023 Outstanding Investigator Awards, with up to $600,000 in direct costs per year over six years.
Over 50 research papers that list top leaders of Dana-Farber Cancer Institute among authors are implicated in an investigation of allegations of data manipulation.Â
Despite the continuing overall decline in cancer death rates—driven by reduction in tobacco use, improvements in early detection, and advances in treatment—the projected number of new diagnoses now tops 2 million for the first time, according to the American Cancer Society’s 2024 Cancer Statistics report.
Regulatory News
Multi-cancer detection tests evoke conflicting reactions—the excitement at their promise is quickly dampened by concerns over the uncertainty of their clinical benefit, very low sensitivity for detecting stage 1 cancers, and the risks that come from subsequent workups.
Free
Medicare has started to pay for navigation for guiding patients through the maze of health care services in settings where treatment involves multiple specialties.
